Navigation Links
Ohr Pharmaceutical Announces Addition of Dr. John Wroblewski to Ophthalmic Scientific Advisory Board
Date:8/7/2013

NEW YORK, Aug. 7, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (NasdaqCM: OHRP) today announced the addition of John J. Wroblewski M.D. to its Scientific Advisory Board ("SAB"). The board, comprised of leading retinal ophthalmology experts, advises the company on its clinical programs, regulatory strategy and provides strategic guidance to support the ongoing development of lead drug candidate Squalamine in multiple neovascular ophthalmic clinical indications, each with sizable commercial markets.

"Squalamine eye drops have the potential to significantly advance the treatment of wet-AMD through a unique mechanism of action which may provide distinct or additional benefits to the anti-VEGF agents currently used to treat these patients," stated Dr. John Wroblewski, retina specialist at Cumberland Valley Retina Consultants. "I am excited to be participating in the OHR-002 wet-AMD clinical trial and look forward to working closely with the Ohr team to evaluate Squalamine eye drops in additional ophthalmic indications where neovascularization plays an important role."

Irach B. Taraporewala, Ph.D., CEO of Ohr Pharmaceutical, commented, "We are delighted to be working with a thought leader and clinical researcher of Dr. Wroblewski's caliber. Our OHR-002 trial to evaluate Squalamine eye drops in wet-AMD continues to progress well, as evidenced by our recently announced completion of the halfway point in enrollment, and the expected availability of interim data in the second quarter of 2014.  We look forward to the contributions Dr. Wroblewski will make during this exciting time for Ohr Pharmaceutical."

John Joseph Wroblewski, M. D., is a board-certified ophthalmologist who has been treating diseases of the retina, macula, and vitreous for twenty-two years.  He is the senior partner of Cumberland Valley Retina Consultants located in Western Maryland and South-Central Pennsylvania.  Doctor Wroblewski is a graduate of the Moorfields Eye Hospital in London, England, and has served as a consultant and medical advisor to several ophthalmic pharmaceutical companies.  He has participated in the design of multiple clinical protocols and has been a Principal Investigator in twenty-three national clinical trials conducted over the past twelve years, all of which investigated the efficacy of different pharmaceutical agents in the treatment of exudative macular degeneration, retinal vein occlusion, and diabetic retinopathy.  Doctor Wroblewski has lectured nationally and internationally and is the founder and president of Retina Care International, a not-for-profit organization actively working since 2005 to help solve the diabetic retinopathy pandemic in the Yucatan Peninsula in Mexico.  Dr. Wroblewski received his M.D. from Georgetown University School of Medicine.

About Squalamine Eye Drops
Squalamine is an anti-angiogenic small molecule with a novel intracellular mechanism of action, which counteracts multiple growth factors implicated in the angiogenesis process. Ohr Pharmaceutical has developed a novel eye drop formulation of Squalamine for the treatment of wet-AMD, designed for self-administration, which may provide several potential advantages over the FDA approved current standards of care which require intravitreal injections directly into the eye.  The drug, using an intravenous administration in over 250 patients in Phase I and Phase II trials for the treatment of wet-AMD, showed favorable biological effect and maintained and improved visual acuity outcomes. In May 2012, the Squalamine Eye Drop program was granted Fast Track Designation by the U.S. FDA. A Phase II randomized, double blind, placebo controlled study (OHR-002) to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of wet-AMD is currently enrolling patients at more than twenty clinical sites in the U.S.

About Ohr Pharmaceutical Inc.
Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP) is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The Company is focused on advancing its pipeline products currently in phase II clinical development: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia. Additional information on the Company can be found at www.ohrpharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: 
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

Contact:
Investor Relations:
Tel: (877) 215-4813
Email: ir@ohrpharmaceutical.com

 


'/>"/>
SOURCE Ohr Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. China is an Attractive Option for Pharmaceutical Outsourcing due to Low Development Costs
2. Isis Pharmaceuticals to Present at the Canaccord Genuity 33rd Annual Growth Conference
3. Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results
4. Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013
5. Alexza Pharmaceuticals to Present at the 2013 Wedbush Life Sciences Management Access Conference
6. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
7. Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock
8. JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2013 FINANCIAL RESULTS
9. Cumberland Pharmaceuticals Reports Second Quarter Financial Results
10. Inovio Pharmaceuticals Responds to Market Activity
11. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... The Society for Non OR Intervention and ... Health & Safety ( PPAHS ) are pleased to ... optimized outcomes for patients undergoing procedures outside of the ... SONORIA and Michael Wong JD, Executive Director of PPAHS ... respective organization,s Boards. SONORIA is an integrated ...
(Date:1/24/2017)... 2017 Transparency Market Research observes ... of 91.6% in the global capsule filler market in ... been leading the overall market for a significant time ... in handling sophisticated designs and manufacturing machines to manage ... research and development to deliver innovative products with new ...
(Date:1/24/2017)... 2017   QR Pharma , Inc., a ... therapies for the treatment of Alzheimer,s, Parkinson,s and ... four world-class key opinion leaders to its Scientific ... Pharma,s previous roster of impressive advisors in order ... the development of the breakthrough mechanism of action ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... ... Bellus Medical, a leader in medical aesthetics, today announced that Marek Dobke, M.D., ... will provide physician oversight for in-house clinical studies and hands-on device training, among other ... Professor of Surgery at UC San Diego Health and is a board certified plastic ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... Need to Thrive , Well-meaning studies such as the Fordham Institute’s High ... better serve top students, such as including gifted or high-achieving students as a ...
(Date:1/24/2017)... ... 2017 , ... Today, Taza Agua, Costa Rica's leading supplier ... to optimize the drinking experience for K-Cup coffee, tea and hot chocolate connoisseurs ... first untouched bottled water purposed exclusively for creating a superior brew. The company ...
(Date:1/24/2017)... ... ... Dreamed: A Novel of Miracles”: a beautiful and poignant glimpse into the unexpected consequences ... life. “Who Would Have Dreamed: A Novel of Miracles” is the creation of published author, ... , Sharon shares that she started her spiritual journey later in life, but mentions, “I ...
(Date:1/24/2017)... ... January 24, 2017 , ... Attention women ... article suggests that autologous fat grafting—taking one’s own fat and putting it ... breast implants. , Cosmetic Surgeon and Medical Director of MilfordMD Cosmetic Dermatology ...
Breaking Medicine News(10 mins):